Indication: Miscellaneous Malignancies
A Phase 2 Study of Olaparib in Combination with Pembrolizumab in Participants with Previously Treated, Homologous Recombination Repair Mutation (HRRm) and/or Homologous Recombination Deficiency (HRD)-
Sub-indication: Miscellaneous Malignancies
Drug Study
Principal Investigator: Mary Gordinier, M.D.Norton Cancer Institute
Sponsor: Merck Sharp & Dohme CORP
Email for more information: GYN-NCIResearch@nortonhealthcare.org
